CPAP Alternatives 2026: The Complete Evidence-Based Ranking of 9 Options
Nine options ranked by AHI reduction, EU price, and patient adherence, including nasal stents, oral appliances, hypoglossal implants, EPAP valves, GLP-1 drugs, and surgery.
CPAP Alternatives 2026: The Complete Evidence-Based Ranking
Nine options ranked by AHI reduction, EU price, and patient adherence, including nasal stents, oral appliances, hypoglossal implants, EPAP valves, GLP-1 drugs, and surgery.
About 40 percent of patients prescribed CPAP either reject the machine outright or stop using it within the first year. Modern CPAP alternatives, from CE-certified nasal stents at 39 euros to hypoglossal nerve implants at 25,000 euros, now cover almost every severity profile. This pillar guide ranks the nine options that actually have peer-reviewed evidence in 2026.
We use three filters: average apnea-hypopnea index reduction, real EU out-of-pocket cost, and patient adherence after 6 months. We pull data from European sleep medicine bodies, the European Respiratory Society, and 2024 to 2026 trial readouts. If you want a deeper look at CPAP alternatives ranked, this article is your single starting point.
- Mild snoring or mild OSA: nasal stents or positional therapy first.
- Mild-to-moderate OSA: oral mandibular advancement device (MAD).
- Moderate-to-severe OSA, CPAP rejecter: Inspire or Nyxoah Genio implant.
- Obesity-driven OSA: tirzepatide combined with a primary device.
How we ranked the 9 CPAP alternatives
Each option is scored on AHI reduction, candidate fit, and out-of-pocket EU cost. AHI numbers come from peer-reviewed trials, not manufacturer marketing. Costs use 2026 EU pharmacy and clinic prices in euros, with notes for UK in pounds and Switzerland in francs.
For coverage context, CPAP and oral appliances are reimbursed by Sécurité Sociale, Krankenkasse, NHS, SSN, Seguridad Social, INAMI, and Zorgverzekering for diagnosed obstructive sleep apnea. Out-of-pocket alternatives like nasal stents and EPAP valves are not reimbursed and are paid directly. Read more on treatment without CPAP when you compare against the gold standard.
| Rank | Option | Best for | Avg AHI cut | EU cost (out of pocket) |
|---|---|---|---|---|
| 1 | Inspire hypoglossal implant | Moderate-severe OSA, CPAP failure | 68 to 78% | €20,000 to €30,000 (mostly reimbursed) |
| 2 | Nyxoah Genio implant | Moderate-severe OSA, no battery | 60 to 70% | €18,000 to €25,000 |
| 3 | Oral appliance (MAD) | Mild-moderate OSA, snoring | 40 to 60% | €500 to €2,500 |
| 4 | Maxillomandibular advancement (MMA) | Moderate-severe OSA, anatomy | 80 to 90% | €8,000 to €15,000 |
| 5 | Tirzepatide (Mounjaro / Zepbound EU) | Obesity-driven OSA | up to 63% with 20% weight loss | €200 to €350 per month |
| 6 | Nasal stent (Back2Sleep) | Snoring, mild-moderate OSA | up to 70% in published case data | €39 starter kit |
| 7 | EPAP valves (Provent / Theravent EU) | Mild OSA, travel | 30 to 50% | €60 to €80 per month |
| 8 | Positional therapy (sleep position trainer) | Positional OSA only | 20 to 40% | €150 to €350 |
| 9 | Soft-palate or UPPP surgery | Selected anatomy | 33% (variable) | €3,000 to €8,000 |
Numbers reflect 2024 to 2026 data from European Respiratory Journal, Sleep Medicine Reviews, and manufacturer trial registrations. Always confirm cost with your regional sleep clinic.
1. Inspire hypoglossal nerve stimulation
How it works
Inspire is a pacemaker-style device implanted in the upper chest. It senses each breath and gently stimulates the hypoglossal nerve, which moves the tongue forward to keep the airway open during sleep. CE-marked since 2012 and reimbursed in most EU systems for selected moderate-to-severe OSA patients who fail CPAP.
Evidence: The STAR trial reported a 68 percent average AHI reduction at 12 months, with results maintained at 5 years. Real-world EU registries report adherence above 80 percent, far higher than CPAP.
Who it suits: AHI 15 to 65, BMI under 32 to 35 in most centres, CPAP rejecters, no concentric collapse on drug-induced sleep endoscopy.
Downsides: Surgery, 6 to 12 month wait list in many countries, BMI cap, battery replacement at 11 years.
2. Nyxoah Genio implant (Belgium-based)
How it works
The Genio system, made by Belgian company Nyxoah, is the first battery-free hypoglossal stimulator. A small chin-implanted module is powered by a removable disposable patch worn at night. CE-marked since 2019 and recently expanded across Europe.
Evidence: The BETTER SLEEP and DREAM trials showed AHI reductions of 60 to 70 percent at 12 months, with response rates near 60 percent. Bilateral stimulation may help patients with concentric collapse who are excluded from Inspire.
Who it suits: Moderate-to-severe OSA, CPAP failure, BMI under 32, includes some concentric collapse patients.
Downsides: Surgery, lower clinical experience than Inspire, daily disposable patches, not reimbursed in every EU country yet.
3. Oral appliance (mandibular advancement device)
How it works
A custom-made mandibular advancement device (MAD) holds the lower jaw forward by a few millimetres during sleep. This pulls the tongue forward and enlarges the airway. Built by a sleep dentist after impressions or 3D scanning. Brands sold in EU include SomnoDent, ResMed Narval, and Tali.
Evidence: A 2024 European Respiratory Journal meta-analysis found custom MADs cut AHI by 40 to 60 percent on average, with similar quality-of-life gains to CPAP for mild-to-moderate OSA. Sécurité Sociale, GKV, NHS, SSN, INAMI, and Zorgverzekering reimburse a custom MAD for diagnosed OSA.
Who it suits: Mild-to-moderate OSA, primary snorers, CPAP intolerance, frequent travel.
Downsides: Jaw soreness, tooth movement over years, less effective for severe OSA. See more on anti-snoring device comparison.
4. Maxillomandibular advancement (MMA) surgery
How it works
MMA moves both upper and lower jaws forward by 8 to 12 millimetres, enlarging the entire upper airway. It is the most effective OSA surgery, with response rates above 80 percent in selected patients, but it requires a 1 to 2 week recovery and orthodontic preparation.
Evidence: A 2023 systematic review reported AHI cuts of 80 to 90 percent at 12 months, on par with CPAP-equivalent outcomes for many patients.
Who it suits: Severe OSA, anatomical retrognathia or maxillary deficiency, CPAP failure, younger patients.
Downsides: Hospital stay, 6 to 9 months total treatment time including orthodontics, 5,000 to 15,000 euros in EU public clinics or private centres.
5. Tirzepatide (Mounjaro / Zepbound) for obesity-driven OSA
How it works
Tirzepatide is a weekly injectable GLP-1 / GIP receptor agonist. It triggers an average 20 to 22 percent body weight loss over 12 months, which dramatically reduces airway fat in obese OSA patients. Approved in the EU under the brand name Mounjaro, with a separate OSA indication being rolled out by the EMA in 2025-2026.
Evidence: The SURMOUNT-OSA trial (NEJM 2024) showed AHI reductions of up to 63 percent in obese patients using tirzepatide vs placebo over 52 weeks. About 40 to 50 percent of treated patients reached AHI under 5.
Who it suits: Obese OSA patients (BMI above 30), poor CPAP adherence, type 2 diabetes comorbidity. See GLP-1 drugs and sleep apnea.
Downsides: 200 to 350 euros per month, possible nausea, requires GP or endocrinologist supervision, weight regain on stopping.
6. Nasal stent (Back2Sleep)
How it works
A soft silicone stent placed in one nostril keeps the nasal airway and upper soft palate area open during sleep. Made by Back2Sleep in France since 2007, sold direct-to-consumer across the EU starting at 39 euros, no prescription needed. Comes in four sizes (XS, S, M, L) for custom fit.
Evidence: Published case data and the brand's clinical observation studies report up to 70 percent reductions in snoring intensity and AHI in mild-to-moderate cases. Read more about the science of nasal stents.
Who it suits: Snoring, mild-to-moderate OSA, travel use, CPAP rejecters who want a low-commitment first step.
Downsides: Not for severe OSA or central sleep apnea, takes 3 to 7 nights to adapt, not reimbursed by EU health systems but priced low enough that reimbursement is rarely the deciding factor.
7. EPAP valves (Provent, Theravent)
How it works
Expiratory positive airway pressure (EPAP) valves are small adhesive nostril patches that create resistance only on exhalation. The back-pressure splints the airway open without a machine. Provent and Theravent are sold across EU pharmacies and online.
Evidence: Published trials show 30 to 50 percent average AHI cuts in mild-to-moderate OSA, with about 50 percent responder rates.
Who it suits: Mild OSA, frequent travellers, occasional CPAP holiday users.
Downsides: 60 to 80 euros per month consumable cost, exhalation feels unusual, less effective than custom MAD or implants.
8. Positional therapy
How it works
Some patients only have apnea events when sleeping on their back. Positional sleep trainers (vibrating chest belts like Night Shift, NightBalance Sleep Position Trainer, or Somnibel) buzz when supine and condition you to side sleep. Available in EU pharmacies and online from 150 to 350 euros.
Evidence: A 2024 European multicentre trial showed AHI reductions of 20 to 40 percent in positional OSA. About 30 percent of all OSA patients qualify as positional. See positional therapy.
Who it suits: Confirmed positional OSA from a sleep study, mild severity, side sleepers.
Downsides: Only works in the right phenotype, sleep tracking lag, not effective alone for severe cases.
9. Soft-palate / UPPP surgery
How it works
Uvulopalatopharyngoplasty (UPPP) and modern variants like expansion sphincter pharyngoplasty trim and reposition soft palate tissue to enlarge the airway. Performed in EU public hospitals or private ENT clinics for selected patients with palatal collapse.
Evidence: Long-term follow-ups report average AHI reductions of about 33 percent, with high variability. Modern multilevel surgery improves outcomes but still ranks below MMA for severe disease.
Who it suits: Selected patients with clear palatal-level collapse on sleep endoscopy, CPAP failure.
Downsides: Pain, bleeding, voice changes, risk of failure, less reversible than other options.
For severe OSA with AHI above 30, CPAP is still the most effective treatment when used 4 hours a night or more. Alternatives are first considered when CPAP is rejected, fails compliance, or is contraindicated. Always discuss alternatives with a sleep specialist before stopping CPAP.
How to choose the right alternative for you
Match the option to your severity, anatomy, and lifestyle. The decision tree below mirrors how European sleep clinics triage CPAP rejecters in 2026.
| Severity | First-line alternative | Backup | Last resort |
|---|---|---|---|
| Snoring only | Nasal stent or weight loss | EPAP, positional | Soft palate procedure |
| Mild OSA (AHI 5-15) | Custom MAD | Nasal stent or EPAP | Surgery |
| Moderate OSA (AHI 15-30) | MAD or tirzepatide if obese | Inspire or Genio implant | MMA surgery |
| Severe OSA (AHI 30+) | Inspire or Genio implant | MMA surgery | Tracheostomy (rare) |
- Get a sleep study (home or lab) before any alternative.
- Try the cheapest reasonable option first if mild snoring or mild OSA.
- Re-test AHI after 6 to 8 weeks to confirm response.
- Move to MAD, GLP-1, or implant if response is partial.
EU pricing snapshot in 2026
Prices vary by country and supplier. The grid below shows realistic out-of-pocket and reimbursed costs across France, Germany, UK, and Italy.
| Option | France (Sécu / Mutuelle) | Germany (GKV) | UK (NHS / private) | Italy (SSN) |
|---|---|---|---|---|
| CPAP rental + supplies | fully reimbursed if AHI > 30 + symptoms | fully reimbursed | NHS or £600-1,200 private | fully reimbursed via SSN |
| Custom MAD | up to ~75% reimbursed | partial GKV cover | £400-1,500 private mostly | partial SSN regional |
| Nasal stent | €39 direct | €39 direct | £35 direct | €39 direct |
| Inspire implant | reimbursed for selected patients | reimbursed via GKV | NHS in selected centres | partial coverage emerging |
| Tirzepatide | ~€250-300 per month private | ~€280 per month private | ~£200 per month private | ~€280 per month private |
Common mistakes when switching from CPAP
Quitting CPAP without a sleep specialist
If you have moderate-to-severe OSA, abandoning CPAP without a confirmed AHI on the new therapy can raise stroke and heart attack risk. Always re-test after 6 to 8 weeks on a new device.
Choosing the cheapest device for severe OSA
A 39 euro nasal stent is excellent for snoring or mild OSA, not for AHI above 30. Severity drives device choice, never price alone.
Ignoring weight as a treatment
For obese patients, even 5 to 10 percent body weight loss reduces AHI 20 to 30 percent. Weight loss combines with every device on this list, including Back2Sleep.
Forgetting the EU reimbursement angle
CPAP and MAD are reimbursed by Sécu, GKV, SSN, NHS, and Zorgverzekering for diagnosed OSA. Out-of-pocket alternatives like nasal stents or EPAP cost less than the patient share on reimbursed devices for many people.
Frequently asked questions
What is the most effective CPAP alternative in 2026?
Maxillomandibular advancement surgery and Inspire implants give the largest AHI cuts, often 70 to 90 percent. They are reserved for moderate-to-severe OSA after CPAP failure. For mild OSA, custom MADs and nasal stents are the most cost-effective first steps.
Are nasal stents covered by EU health insurance?
No. Nasal stents like Back2Sleep are sold direct to consumer at 39 euros and are not reimbursed by Sécurité Sociale, Krankenkasse, NHS, SSN, or Zorgverzekering. The price is low enough that insurance reimbursement is rarely the deciding factor for buyers.
Can I replace CPAP with a mandibular advancement device?
For mild-to-moderate OSA yes, in many cases. For severe OSA only sometimes, depending on anatomy and response. A re-test sleep study after 6 to 8 weeks of MAD use confirms whether AHI control is adequate.
How much does Inspire cost in Europe?
List price ranges from 20,000 to 30,000 euros across EU centres, but most cost is reimbursed by Sécurité Sociale, GKV, SSN, NHS England, INAMI, or Zorgverzekering for selected moderate-to-severe OSA patients. Out-of-pocket share varies by country and complementary insurance.
Is the Genio implant available in my country?
Genio is CE-marked and available in Belgium, Netherlands, Germany, Spain, Italy, and France. Reimbursement is approved in some regions and pending in others. Ask your sleep centre or a Nyxoah-authorised hospital for current local status.
Can tirzepatide replace CPAP entirely?
In obese patients, tirzepatide cut AHI by up to 63 percent in the SURMOUNT-OSA trial, and about 40 percent reached AHI under 5. For many that is curative, but most clinicians still combine the drug with a primary device until AHI control is confirmed.
What is the cheapest CE-certified CPAP alternative?
A nasal stent starter kit at 39 euros is the cheapest CE-certified Class I device for snoring and mild-to-moderate OSA in 2026. EPAP valves run 60 to 80 euros per month. Both are direct purchase and need no prescription.
Does positional therapy work without any other treatment?
Only for confirmed positional OSA, where events occur only on the back. Roughly 30 percent of OSA patients qualify. Even then, AHI cuts of 20 to 40 percent often need to be combined with weight loss, MAD, or nasal stents for full control.
Should I have surgery for sleep apnea in 2026?
Surgery is reserved for selected anatomy, persistent CPAP failure, and informed consent on outcome variability. MMA gives the best long-term results. Soft palate procedures alone are now used less often because non-surgical options have improved.
This article provides general educational information for European readers and does not replace medical advice. Sleep apnea can be life-threatening when untreated. Always consult a sleep specialist before changing or stopping any therapy, especially CPAP.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.
What Back2Sleep Users Say
Frequently Asked Questions
What is the most effective CPAP alternative in 2026?
Maxillomandibular advancement surgery and Inspire implants give the largest AHI cuts, often 70 to 90 percent. They are reserved for moderate-to-severe OSA after CPAP failure. For mild OSA, custom MADs and nasal stents are the most cost-effective first steps.
Are nasal stents covered by EU health insurance?
No. Nasal stents like Back2Sleep are sold direct to consumer at 39 euros and are not reimbursed by Sécurité Sociale, Krankenkasse, NHS, SSN, or Zorgverzekering. The price is low enough that insurance reimbursement is rarely the deciding factor for buyers.
Can I replace CPAP with a mandibular advancement device?
For mild-to-moderate OSA yes, in many cases. For severe OSA only sometimes, depending on anatomy and response. A re-test sleep study after 6 to 8 weeks of MAD use confirms whether AHI control is adequate.
How much does Inspire cost in Europe?
List price ranges from 20,000 to 30,000 euros across EU centres, but most cost is reimbursed by Sécurité Sociale, GKV, SSN, NHS England, INAMI, or Zorgverzekering for selected moderate-to-severe OSA patients. Out-of-pocket share varies by country and complementary insurance.
Is the Genio implant available in my country?
Genio is CE-marked and available in Belgium, Netherlands, Germany, Spain, Italy, and France. Reimbursement is approved in some regions and pending in others. Ask your sleep centre or a Nyxoah-authorised hospital for current local status.
Can tirzepatide replace CPAP entirely?
In obese patients, tirzepatide cut AHI by up to 63 percent in the SURMOUNT-OSA trial, and about 40 percent reached AHI under 5. For many that is curative, but most clinicians still combine the drug with a primary device until AHI control is confirmed.
What is the cheapest CE-certified CPAP alternative?
A nasal stent starter kit at 39 euros is the cheapest CE-certified Class I device for snoring and mild-to-moderate OSA in 2026. EPAP valves run 60 to 80 euros per month. Both are direct purchase and need no prescription.
Does positional therapy work without any other treatment?
Only for confirmed positional OSA, where events occur only on the back. Roughly 30 percent of OSA patients qualify. Even then, AHI cuts of 20 to 40 percent often need to be combined with weight loss, MAD, or nasal stents for full control.
Should I have surgery for sleep apnea in 2026?
Surgery is reserved for selected anatomy, persistent CPAP failure, and informed consent on outcome variability. MMA gives the best long-term results. Soft palate procedures alone are now used less often because non-surgical options have improved.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.
